Winegarner, Andrew
Miki, Atsuya http://orcid.org/0000-0002-5618-7287
Kumoi, Miho
Ishida, Yuichiro
Wakabayashi, Taku
Sakimoto, Susumu
Usui, Shinichi
Matsushita, Kenji
Nishida, Kohji
Article History
Received: 7 June 2018
Revised: 11 September 2018
Accepted: 16 October 2018
First Online: 30 October 2018
Compliance with ethical standards
:
: All potential conflicts of interests are listed as follows: Miki A received honorarium from Kowa Pharmaceuticals, Pfizer Japan, Santen Pharmaceuticals, Alcon Japan, Otsuka Pharmaceutical, Novartis Pharma, R-Tech Ueno, Senju Pharmaceutical, Topcon, Ellex Inc., and Alcon Pharma. Nishida K received research support from Otsuka Pharmaceutical, AMO Japan, Topcon, Menicon, Wakamoto, Senju Pharmaceutical, Rohto Pharmaceutical, Santen Pharmaceutical, Novartis Pharma, Alcon Japan, Pfizer Japan, Hoya, Bayer Yakuhin, MSD Japan, and Kowa Pharmaceuticals, and honorarium from Senju Pharmaceutical, Pfizer Japan, Santen Pharmaceutical, Otsuka Pharmaceutical, Novartis Pharma, Alcon Japan, Hoya, Boehringer Ingelheim Japan, Bayer Yakuhin, Kowa Pharmaceuticals, SEED, Chuo Sangio, and Johnson & Johnson Japan. Winegarner A, Kumoi M, Ishida Y, Wakabayashi T, Sakimoto S, Usui S, and Matsushita K declared no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.